Sandoz settles US antitrust case for $275m

Sandoz settled a US Generic Drug Antitrust Class Action for $275 million, with additional provisions for outstanding claims, marking a significant step in resolving litigation.

Olema stock surges on Novartis deal and $250M private placement

Novartis upgrades sales forecast

Earnings call: Novartis raises 2024 guidance on strong Q3 performance

Novartis reported strong Q3 2024 results, with 10% sales growth and a 20% rise in core operating income, raising financial guidance amid optimism despite potential challenges.

Jefferies downgrades Novartis despite long-term optimism

Jefferies downgraded Novartis to 'hold', citing near-term caution despite long-term optimism. Delayed product launches and modest growth projections temper short-term expectations, though several key drugs promise future success.